Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Healthcare Biotechnology
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc > SONA RESULTS
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(306)
•••
Comment by whatdoiknow123on Nov 09, 2020 6:31pm
198 Views
Post# 31867532

RE:RE:SONA RESULTS

RE:RE:SONA RESULTS
Kusanation wrote: Which results are you talking about? Did I miss something ?



The results from the in-field testing carried out a few months ago  in SA and detailed in a release today that was obviously the cause of the massive rebound in SP this afternoon.

The results are not new but SONA , for the first time, have broken down the results into patient types explaining their analysis of the results which clearly indicate that the SONA test is ideal for:

1. detecting the Asymptomatic
2. detecting patients very early in their infectious process 
3. detecting patients with low viral loads

It showed 100% Sensitivity in these groups which is exceptional and far superior to results shown so far by any test either available or known to be in development.

These results emphasise the SONA test potential.

They also talked about the SA Approval Submission and CE Certification which ,I believe, they themselves have not specifically commented on before although others have.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities